WO2006081430A3 - Leader sequences for directing secretion of polypeptides and methods for production thereof - Google Patents

Leader sequences for directing secretion of polypeptides and methods for production thereof Download PDF

Info

Publication number
WO2006081430A3
WO2006081430A3 PCT/US2006/002951 US2006002951W WO2006081430A3 WO 2006081430 A3 WO2006081430 A3 WO 2006081430A3 US 2006002951 W US2006002951 W US 2006002951W WO 2006081430 A3 WO2006081430 A3 WO 2006081430A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
leader sequences
production
methods
heterologous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/002951
Other languages
French (fr)
Other versions
WO2006081430A2 (en
WO2006081430A9 (en
Inventor
Robert Forgan Halenbeck
Elizabeth Bosch
Thomas Linnemann
Ernestine Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Five Prime Therapeutics Inc
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Priority to AU2006207999A priority Critical patent/AU2006207999A1/en
Priority to US11/883,065 priority patent/US20080286834A1/en
Priority to AT06719694T priority patent/ATE454455T1/en
Priority to CA002589895A priority patent/CA2589895A1/en
Priority to JP2007553266A priority patent/JP2008528033A/en
Priority to DK06719694.9T priority patent/DK1841874T3/en
Priority to DE602006011574T priority patent/DE602006011574D1/en
Priority to EP06719694A priority patent/EP1841874B1/en
Publication of WO2006081430A2 publication Critical patent/WO2006081430A2/en
Publication of WO2006081430A9 publication Critical patent/WO2006081430A9/en
Publication of WO2006081430A3 publication Critical patent/WO2006081430A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention provides leader sequences that are useful for the production of heterologous secretable polypeptides; heterologous secreted polypeptides; nucleic acid constructs that encode such leader sequences and heterologous secreted polynucleotides; vectors that contain such nucleic acid constructs; recombinant host cells that contain such nucleic acid constructs; vectors, polypeptides, and methods of making and using such secreted polypeptides with such heterologous leader sequences.
PCT/US2006/002951 2005-01-27 2006-01-27 Leader sequences for directing secretion of polypeptides and methods for production thereof Ceased WO2006081430A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2006207999A AU2006207999A1 (en) 2005-01-27 2006-01-27 Leader sequences for directing secretion of polypeptides and methods for production thereof
US11/883,065 US20080286834A1 (en) 2005-01-27 2006-01-27 Leader Sequences For Directing Secretion of Polypeptides and Methods For Production Thereof
AT06719694T ATE454455T1 (en) 2005-01-27 2006-01-27 GUIDING SEQUENCES FOR GUIDING POLYPEPTIDE SECRETION AND METHOD FOR PRODUCTION
CA002589895A CA2589895A1 (en) 2005-01-27 2006-01-27 Leader sequences for directing secretion of polypeptides and methods for production thereof
JP2007553266A JP2008528033A (en) 2005-01-27 2006-01-27 Leader sequence for detecting secretion of a polypeptide and method for its production
DK06719694.9T DK1841874T3 (en) 2005-01-27 2006-01-27 Lead sequences to guide secretion of polypeptides and methods for their preparation
DE602006011574T DE602006011574D1 (en) 2005-01-27 2006-01-27 GUIDANCE SEQUENCES FOR THE MANAGEMENT OF POLYPEPTIDE SECRETION AND METHOD OF MANUFACTURE
EP06719694A EP1841874B1 (en) 2005-01-27 2006-01-27 Leader sequences for directing secretion of polypeptides and methods for production thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64701305P 2005-01-27 2005-01-27
US60/647,013 2005-01-27

Publications (3)

Publication Number Publication Date
WO2006081430A2 WO2006081430A2 (en) 2006-08-03
WO2006081430A9 WO2006081430A9 (en) 2006-11-30
WO2006081430A3 true WO2006081430A3 (en) 2007-04-05

Family

ID=36741080

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/002951 Ceased WO2006081430A2 (en) 2005-01-27 2006-01-27 Leader sequences for directing secretion of polypeptides and methods for production thereof

Country Status (9)

Country Link
US (1) US20080286834A1 (en)
EP (1) EP1841874B1 (en)
JP (2) JP2008528033A (en)
AT (1) ATE454455T1 (en)
AU (1) AU2006207999A1 (en)
CA (1) CA2589895A1 (en)
DE (1) DE602006011574D1 (en)
DK (1) DK1841874T3 (en)
WO (1) WO2006081430A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10660316B2 (en) 2016-11-04 2020-05-26 Akeagen, Inc. Genetically modified non-human animals and methods for producing heavy chain-only antibodies

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2336832T3 (en) 2005-07-22 2010-04-16 Five Prime Therapeutics, Inc. COMPOSITIONS AND PROCEDURES TO TREAT DISEASES WITH FGFR FUSION PROTEINS.
EP1937815B1 (en) 2005-09-13 2015-05-13 National Research Council of Canada Methods and compositions for modulating tumor cell activity
US9060961B2 (en) * 2006-11-09 2015-06-23 University Of Washington Molecules and methods for treatment and detection of cancer
WO2009056330A1 (en) * 2007-10-31 2009-05-07 Eth Zurich Soluble truncated apom proteins and medical uses thereof
US20110212055A1 (en) * 2008-03-25 2011-09-01 Commissiong John W Neurodegenerative disorders
FR2933773B1 (en) * 2008-07-10 2013-02-15 Biomerieux Sa METHOD FOR DETERMINING THE ISOMERASE DISULFIDE PROTEIN FOR IN VITRO DIAGNOSIS OF COLORECTAL CANCER
CN102171343B (en) 2008-08-04 2017-07-14 戊瑞治疗有限公司 FGFR extracellular domain acidic region mutein
WO2010075194A1 (en) * 2008-12-22 2010-07-01 St. Jude Children's Research Hospital Prokaryotic expression of soluble, active dkk
JP2010183885A (en) * 2009-02-13 2010-08-26 Kobe Univ Method for producing protein and expression vector used therefor
EP2478003A4 (en) 2009-09-15 2013-05-29 Five Prime Therapeutics Inc HAIR GROWTH METHODS USING THE EXTRACELLULAR DOMAINS OF FGFR4
CA2780457A1 (en) 2009-11-13 2011-05-19 Five Prime Therapeutics, Inc. Use of fgfr1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in fgfr2
WO2011063523A1 (en) 2009-11-24 2011-06-03 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
EP2512501A4 (en) 2009-12-17 2014-01-01 Five Prime Therapeutics Inc Hair growth methods using fgfr3 extracellular domains
SMT201900074T1 (en) 2010-05-04 2019-02-28 Five Prime Therapeutics Inc Antibodies that bind csf1r
WO2012006027A1 (en) 2010-06-28 2012-01-12 Five Prime Therapeutics, Inc. Fzd8 extracellular domains and fzd8 extracellular domain fusion molecules and treatments using same
EP2444495A1 (en) * 2010-10-20 2012-04-25 Algenics Secretion of recombinant polypeptides in the extracellular medium of diatoms
BR112013012041A2 (en) 2010-11-15 2016-11-08 Five Prime Therapeutics Inc '' fgfr1 extracellular domain combination therapies "
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
CA2824805A1 (en) 2011-01-14 2012-07-19 Five Prime Therapeutics, Inc. Il-27 antagonists for treating inflammatory diseases
CA2855818A1 (en) 2011-11-14 2013-05-23 Five Prime Therapeutics, Inc. A method of treating lung cancer having an fgfr1 gene amplification or fgfr1 overexpression
WO2013123588A1 (en) 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
KR20150018533A (en) 2012-05-11 2015-02-23 파이브 프라임 테라퓨틱스, 인크. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csfir)
WO2013185069A1 (en) 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Pulmonary delivery of mrna to non-lung target cells
CN104684582A (en) 2012-08-31 2015-06-03 戊瑞治疗有限公司 Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
EP2929035A1 (en) 2012-12-07 2015-10-14 Shire Human Genetic Therapies, Inc. Lipidic nanoparticles for mrna delivering
EP2970940B1 (en) 2013-03-14 2018-07-25 Translate Bio, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
CN105452296B (en) 2013-08-01 2020-09-25 戊瑞治疗有限公司 Afucosylated anti-FGFR 2IIIB antibodies
CN113350501A (en) 2014-06-23 2021-09-07 戊瑞治疗有限公司 Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
AU2015339306B2 (en) 2014-10-29 2021-07-22 Bristol-Myers Squibb Company Combination therapy for cancer
EA201791421A1 (en) 2014-12-22 2017-10-31 Файв Прайм Терапьютикс, Инк. ANTIBODIES AGAINST CSF1R FOR THE TREATMENT OF PVNS
RS60614B1 (en) 2015-03-23 2020-08-31 Jounce Therapeutics Inc Antibodies to icos
BR112017020952A2 (en) 2015-04-13 2018-07-10 Five Prime Therapeutics Inc cancer treatment method, composition and use of composition
CA2998208A1 (en) 2015-10-22 2017-04-27 Jounce Therapeutics, Inc. Gene signatures for determining icos expression
US10799559B2 (en) 2016-04-25 2020-10-13 Five Prime Therapeutics, Inc. NOPE for treatment of pathological muscle loss and weakness
RS62589B1 (en) 2016-11-02 2021-12-31 Jounce Therapeutics Inc Antibodies to pd-1 and uses thereof
US20190330376A1 (en) * 2016-12-29 2019-10-31 Development Center For Biotechnology Peptides derived from kininogen-1 for protein drugs in vivo half-life extensions
JP2020512357A (en) 2017-03-31 2020-04-23 ファイブ プライム セラピューティクス， インコーポレイテッド Combination therapy for cancer using anti-GITR antibody
US20200024351A1 (en) 2017-04-03 2020-01-23 Jounce Therapeutics, Inc. Compositions and Methods for the Treatment of Cancer
AU2018281334A1 (en) 2017-06-06 2019-12-19 Kindred Biosciences, Inc. Erythropoietin and analogs for veterinary use
CA3087166A1 (en) 2017-12-22 2019-06-27 Jounce Therapeutics, Inc. Antibodies to lilrb2
TWI819024B (en) 2018-07-09 2023-10-21 美商戊瑞治療有限公司 Antibodies binding to ilt4
CN113613727A (en) * 2019-01-11 2021-11-05 嘉立医疗科技(广州)有限公司 Multispecific pre-chemokine therapeutic Proteins (PARKs) and methods of making and using same
JP7810554B2 (en) 2019-03-01 2026-02-03 アケロイス バイオファーマ， インコーポレイテッド Methods and uses of modulating CD160 function in antigen-specific immune cells
WO2021178001A1 (en) * 2020-03-05 2021-09-10 Curie Co. Inc. Methods for cell free protein expression of mature polypeptides derived from zymogens and proproteins
CN117964757A (en) 2020-02-14 2024-05-03 吉利德科学公司 Antibodies and fusion proteins binding to CCR8 and uses thereof
US20230303695A1 (en) 2020-08-10 2023-09-28 Tengfei XIAO Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8
WO2023235699A1 (en) 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712114A (en) * 1995-06-06 1998-01-27 Basf Aktiengesellschaft Compositions for expression of proteins in host cells using a preprocollagen signal sequence
ES2183601T3 (en) * 1998-08-17 2003-03-16 Europ Lab Molekularbiolog METHOD FOR PURIFYING COMPLEXES OF BIOMOLECULES OR PROTEINS.
US20080242603A1 (en) * 2004-02-20 2008-10-02 Yan Wang Novel Apo2L and IL-24 Polypeptides, Polynucleotides, and Methods of Their Use
CA2574654C (en) * 2004-07-22 2014-02-18 Five Prime Therapeutics, Inc. Compositions and methods of use for mgd-csf in disease treatment

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHOI J H ET AL: "Secretory and extracellular production of recombinant proteins using Escherichia coli", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, vol. 64, no. 5, June 2004 (2004-06-01), pages 625 - 635, XP002402621, ISSN: 0175-7598 *
LO K-M ET AL: "High level expression and secretion of Fc-X fusion proteins in mammalian cells", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 11, no. 6, June 1998 (1998-06-01), pages 495 - 500, XP002125745, ISSN: 0269-2139 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10660316B2 (en) 2016-11-04 2020-05-26 Akeagen, Inc. Genetically modified non-human animals and methods for producing heavy chain-only antibodies
US11832598B2 (en) 2016-11-04 2023-12-05 Akeagen, Inc. Genetically modified non-human animals and methods for producing heavy chain-only antibodies

Also Published As

Publication number Publication date
AU2006207999A1 (en) 2006-08-03
US20080286834A1 (en) 2008-11-20
DE602006011574D1 (en) 2010-02-25
EP1841874B1 (en) 2010-01-06
DK1841874T3 (en) 2010-05-17
EP1841874A2 (en) 2007-10-10
JP2008528033A (en) 2008-07-31
JP2009131268A (en) 2009-06-18
CA2589895A1 (en) 2006-08-03
ATE454455T1 (en) 2010-01-15
WO2006081430A2 (en) 2006-08-03
WO2006081430A9 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
ATE454455T1 (en) GUIDING SEQUENCES FOR GUIDING POLYPEPTIDE SECRETION AND METHOD FOR PRODUCTION
WO2001068848A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002008288A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002024888A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000077037A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2005071088A3 (en) Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of use thereof
EP1666597A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001046420A8 (en) Il-17 and il-17r homologous polypeptides and therapeutic uses thereof
WO2005001064A3 (en) Polypeptides having alpha-amylase activity and polypeptides encoding same
AU3774300A (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1672070A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2006078256A3 (en) Polypeptides having xylanase activity and polynucleotides encoding same
ATE492633T1 (en) POLYPEPTIDES WITH CELLOBIOHYDROLASE ACTIVITY AND POLYNUCLEOTIDES CODING THEREFOR
WO2006053021A3 (en) Methods for engineering polypeptide variants via somatic hypermutation and polypeptides made thereby
WO2000056889A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2010049807A3 (en) T7 dual promoter-based vector system for recombinant expression of polypeptides
WO2007095300A3 (en) Plant chimeric binding polypeptides for universal molecular recognition
WO2004025264A3 (en) Rapidly degraded reporter fusion proteins
ATE532861T1 (en) EXPRESSION VECTOR
WO2005049806A3 (en) Novel nucleic acids and polypeptides
WO2002016611A3 (en) Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
WO2004034780A3 (en) Method of producing recombinant proteins in the mammary gland of non-transgenic mammals
WO2005012341A3 (en) Pichia methanolica secretory signal
WO2004087886A3 (en) Modified adenoviral e1a constructs and methods of use thereof
WO2020185669A3 (en) Fusion polypeptides

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2006207999

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2589895

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2006207999

Country of ref document: AU

Date of ref document: 20060127

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007553266

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2006719694

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11883065

Country of ref document: US